A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516004-42-01

Acronym

CA209-142

Enrollment

143

Registered

2024-10-01

Start date

2014-05-14

Completion date

2024-10-01

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MSI Negative Colorectal Cancer, MSI Positive Colorectal Cancer

Brief summary

Objective response rate (ORR) in all MSI-High and non-MSI-High subjects as determined by Investigators

Detailed description

ORR in all MSI-H and non-MSI-H subjects based on IRRC

Interventions

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

DRUGIpilimumab

DRUGDARZALEX 20 mg/mL concentrate for solution for infusion

DRUGRelatlimab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective response rate (ORR) in all MSI-High and non-MSI-High subjects as determined by Investigators	—

Secondary

Measure	Time frame
ORR in all MSI-H and non-MSI-H subjects based on IRRC	—

Countries

Belgium, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026